Ticagrelor gets FDA nod for DAPT in high-risk patients with CAD
June 2, 2020
The new indication is based on THEMIS, which comprised patients with CAD and type 2 diabetes without previous MI or stroke and showed clinical benefit, but also bleeding concerns.
FDA approves dapagliflozin for low-EF heart failure
May 7, 2020
The approval based on DAPA-HF makes dapagliflozin (Farxiga) the only drug in its class to be indicated for heart failure in the absence of diabetes.